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LIST OF ABBREVIATIONS AND RELEVANT DEFINITIONS  
 
ABR ABR form, General Assessment and Registration form, is the application 
form that is required for submission to the accredited Ethics Committee (In 
Dutch, ABR = Algemene Beoordeling en Registratie) 
AC Abdominal Circumference 
ACE Angiotensin Converting Enzyme 
AE Adverse Event 
BP  Blood Pressure 
BPD BronchoPulmonary Dysplasia 
BSID Bayley Scales of Infant Development 
CCMO Central Committee on Research Involving Human Subjects; in Dutch: 
Centrale Commissie Mensgebonden Onderzoek 
CBCL Child Behaviour CheckList 
CNS Central Nervous System 
CP Cerebral Palsy 
CTG Cardiotocography 
DSMB Data Safety Monitoring Board 
EDF End Diastolic Flow 
EFW Estimate of Fetal Weight 
EudraCT European drug regulatory affairs Clinical Trials  
FGR Fetal Growth Restriction 
GCP Good Clinical Practice 
GMFCS Gross Motor Function Classification Scale -questionnaire  
GMP Good Manufacturing Practice 
HELLP Hemolysis Elevated Liver enzymes Low Platelets 
IC Informed Consent 
ICH IntraCerebral Hemorrhage 
IMP Investigational Medicinal Product  
IMPD Investigational Medicinal Product Dossier  
LMP Last Menstrual Period 
MDI Mental Developmental Index 
METC  Medical research ethics committee (MREC); in Dutch: medisch ethische 
toetsing commissie (METC) 
MgSO4 Magnesium Sulphate 
MRI Magnetic Resonance Imaging 
NEC Necrotising EnteroColitis 
NICU Neonatal Intensive Care Unit 
PDI Psychomotor Developmental Index 
PlGF Placental Growth Factor 
PVL PeriVentricular Leukomalacia 
RCT Randomised Controlled Trial 
RN Research Nurse 
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ROP Retinopathy Of Prematurity 
(S)AE (Serious) Adverse Event  
SPC Summary of Product Characteristics (in Dutch: officiële productinfomatie 
IB1-tekst) 
Sponsor The sponsor is the party that commissions the organisation or performance 
of the research, for example a pharmaceutical 
company, academic hospital, scientific organisation or investigator. A party 
that provides funding for a study but does not commission it is not 
regarded as the sponsor, but referred to as a subsidising party. 
STV Short-Term Variation 
SUSAR Suspected Unexpected Serious Adverse Reaction 
Wbp Personal Data Protection Act (in Dutch: Wet Bescherming Persoonsgevens) 
WMO Medical Research Involving Human Subjects Act (in Dutch: Wet Medisch-
wetenschappelijk Onderzoek met Mensen 
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SUMMARY 
 
Rationale: Severe, early-onset fetal growth restriction (FGR) due to placental insufficiency is 
associated with a high risk of perinatal morbidity with long-lasting sequelae and mortality. 
Placental insufficiency is the result of abnormal formation and function of the placenta 
(placentation) with inadequate remodelling of the maternal spiral (uteroplacental) arteries. 
There is currently no therapy available with demonstrated effectiveness. Evidence suggests 
Sildenafil citrate improves uteroplacental blood flow, growth, and meaningful outcomes.  
Objective: To evaluate the effectiveness of sildenafil (versus placebo) in achieving healthy 
perinatal survival. 
Study design: Multicenter nationwide randomized placebo-controlled clinical trial. 
Study population: Women with a singleton pregnancy between 20 and 30 weeks with 
severe fetal growth restriction of likely placental origin, and with estimated significant 
likelihood of perinatal death. 
Intervention: Sildenafil 25mg or placebo tablet orally three times daily. 
Main study parameters/endpoints: Perinatal healthy survival, i.e. survival without severe 
neonatal morbidity at term age.  
Nature and extent of the burden and risks associated with participation, benefit and 
group relatedness: Taking tablets three times daily. No additional ultrasounds, other than 
standard clinical protocol, one extra blood sample at inclusion. No risks anticipated, 
unexpected medication-associated risks can‟t be excluded on beforehand. 
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1. INTRODUCTION AND RATIONALE 
 
An estimated 700 to 900 cases of severe early-onset fetal growth restriction are managed 
yearly in the academic institutions. This patient group consumes disproportionate amounts of 
care and has a high likelihood of premature delivery, both for fetal and for secondary 
maternal indications such as the development of the maternal syndrome of pre-eclampsia. 
As these FGR children are born very preterm, they carry significant risks of neonatal 
mortality, major and minor morbidity, and long-term health sequelae. These are not only 
strongly gestational-age related, but also related to FGR. The effect of severe early- onset 
FGR is particularly significant: less than a third of these fetuses will survive their uniform 
neonatal intensive care unit (NICU) stay (if they are born alive) without significant 
neurodevelopmental sequelae. Survival rates for severely growth-restricted fetuses very 
remote from term (<28 weeks‟ gestation) vary between 7-33%.  
Currently, there are no specific evidence-based therapies for early-onset severe fetal growth 
restriction. In the absence of therapeutic interventions, standard management consists of 
intensive monitoring and counselling. Non-specific interventions include primarily lifestyle 
modifications such as reducing or stopping work, stopping aerobic exercise, rest at home, 
and hospital admission for rest and surveillance. These interventions, which are not 
supported by sound evidence of efficacy, are used in the belief that rest will reduce the steal 
from the uteroplacental circulation to the glutei and quadriceps muscles. The other 
intervention is that of increased fetal and maternal surveillance in the period of fetal viablity, 
so that decisions around management and timing of delivery can be made. The role of fetal 
surveillance by ultrasound and cardiotocography is clear; the key facet of maternal 
surveillance is to monitor the secondary development of the dangerous maternal syndrome 
of pre-eclampsia that will ultimately complicate approximately 40% of these pregnancies. 
Effective amelioration of the placental insufficiency would add tremendously to the 
therapeutic arsenal.  
Doppler waveform analysis of pregnancies complicated by FGR suggests compromised 
uteroplacental circulation and placental hypoperfusion. There is ample evidence from mouse 
models of growth restriction that sildenafil increases average pup birth weight, including 
improving intermediate parameters of uteroplacental blood flow (umbilical artery, uterine 
artery). Sildenafil citrate may thus offer a potential therapeutic strategy to improve 
uteroplacental blood flow in human pregnancies complicated by severe fetal growth 
restriction of placental origin. There is evidence to support the effect of sildenafil in humans. 
A small trial in women with early pre-eclampsia (the maternal expression of the state of 
placental insufficiency) showed no effect on pre-eclampsia, but a strong effect on birth 
weight. Also, evidence from a cohort study by collaborators in Vancouver showed a tendency 
towards more liveborn children that survived intact to primary discharge after sildenafil 
therapy. From all observations thus far there are no indications that sildenafil in the second 
trimester has significant fetotoxicity.  
On the basis of preliminary research, centers are already adopting the treatment with 
sildenafil. There is however significant uncertainty regarding true health benefits. Moreover, 
potential harm is not yet excluded. Fetotoxicity is unlikely, since this has not been described 
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yet, but theoretically possible. For this reason evidence from randomised trials is needed 
before widespread implementation.  
.  
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OBJECTIVES 
 
The Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth 
Restriction) Trial is a double-blind randomised controlled trial (RCT) designed to evaluate 
whether in pregnant women with severe early-onset FGR of placental origin, Sildenafil citrate 
compared with placebo increases the likelihood of intact perinatal survival until term age. 
This is defined by survival to term age without evidence of either severe central nervous 
system (CNS) injury (by ultrasound and/or magnetic resonance imaging [MRI]) or non-CNS 
severe morbidity (bronchopulmonary dysplasia, retinopathy of prematurity, or necrotising 
enterocolitis requiring surgery).  
The secondary objectives of study are 
1) to evaluate whether Sildenafil citrate, compared to placebo, increases the likelihood of 
improved fetal growth velocity assessed by ultrasound abdominal circumference 
measurements (AC); 
2) to evaluate whether Sildenafil citrate, compared to placebo, increases the likelihood of 
age-adequate performance on the two-year Bayley scales of infant development (BSID)-III 
(composite cognitive score and composite motor score); 
3) to assess co-incidence and severity of the maternal syndrome of pre-eclampsia / HELLP-
syndrome 
4) to evaluate fetal and placental dopplers at study entrance and development of Doppler 
parameters during treatment 
5) to evaluate the role of the placenta(bed) in early severe FGR and the influence of 
Sildenafil 
Announced subgroup analyses: 
to evaluate the effect of Sildenafil on the abovementioned outcome measures, in subgroups 
defined by a) an abnormal or normal serum level of placental growth factor (PlGF); b) other 
patient characteristics available at baseline such as gestational age, estimated fetal weight. 
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2. STUDY DESIGN 
Double-blind randomized placebo-controlled trial, in all ten Dutch perinatal tertiary care 
centers, during 2014-2017. 
 
The ten Dutch perinatal tertiary care centers are: 
- Academisch Medisch Centrum, Amsterdam 
- Maxima Medisch Centrum, Veldhoven 
- Leids Universitair Medisch Centrum, Leiden 
- Isala Klinieken, Zwolle 
- VU Medisch Centrum, Amsterdam 
- Maastricht Universitair Medisch Centrum, Maastricht 
- Universitair Medisch Centrum Groningen, Groningen 
- Radboud Medisch Centrum, Nijmegen 
- Erasmus Medisch Centrum, Rotterdam 
- Universitair Medisch Centrum Utrecht, Utrecht 
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3. STUDY POPULATION 
3.1 Population (base)  
Dutch pregnant women referred to tertiary care referral centers for evaluation and 
management of severe early-onset fetal growth restriction 
3.2 Inclusion criteria 
Inclusion criteria ((I OR II) AND III):  
I. at 200-276 weeks: an ultrasound measurement of the fetal abdominal 
circumference (AC) <3rd percentile for gestational age or an ultrasound estimate of 
fetal weight (EFW) <5th percentile 
OR 
II. at 280-296 weeks: an ultrasound estimate of fetal weight (EFW) <700 grams 
using Hadlock C formula 
AND 
III. likely placental origin defined by (a AND/OR b AND/OR c AND/OR d) 
a. the presence of uterine artery notching  
b. abnormal flow velocity patterns of the umbilical artery or middle 
cerebral artery 
c. maternal hypertensive disorders 
d. low PlGF in point-of-care assessment 
 
3.3 Exclusion criteria 
I. Plan to terminate pregnancy for maternal or fetal indication within days 
II. Known multiple pregnancy 
III. Identified congenital anomalies or congenital infection 
IV. Maternal age at eligibility <18 years 
V. Cocaine use 
VI. Current use of sildenafil 
VII  Current use of cyp3A5 inhibitors: amiodaron, azitromycine, ciclosporine, 
claritromycine, diltiazem, erytromycine, fluconazol, itraconazol, ketoconazol, verapamil, 
voriconazol. 
VIII  Recent myocardial infarction or stroke 
  
3.4 Sample size calculation 
Assumptions for power calculations are made on the basis of clinical relevance and a pilot 
cohort[1]. In the pilot cohort a 29% rate of intact survival until discharge (placebo-treated) vs 
50% (Sildenafil-treated) was seen. We have decided for a difference of 15% to be clinically 
relevant. A 29% rate of intact survival until discharge (placebo-treated) vs 44% (Sildenafil-
treated), with an α of 0.05, we will have 80% power to detect this difference if we randomise 
161 women per group. Therefore, accepting a 10% drop-out rate, the total sample size will 
be 354 women. We have a history of very low rates of loss to follow-up in our RCTs. Also, we 
shall minimise loss to follow-up by having the site study co-ordinator establish a close 
relationship with the study participants, through regular study contacts (at the planned weekly 
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antenatal assessments (minimum), during hospitalisation(s), and at delivery, as applicable) 
and the availability to answer any questions about the Trial. 
 
The 10 tertiary care centers in the Dutch Consortium for women's health and reproductivity 
studies each see an approximate 3-4 patients with severe fetal growth restriction of likely 
placental origin every month. With an expected uptake of the trial in 50% of patients (missed 
inclusions from failure to seek informed consent, denial of informed consent) each center 
may be able to recruit 20 patients per year. With some centers expected not to recruit 
optimally, a sum total of 120 patients per year is realistic. Enrolment of participants will be 
over 3-year duration.  The clinical outcomes for non-consenting women will be tracked to 
evaluate the external validity of the STRIDER Trial findings.  
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4. TREATMENT OF SUBJECTS 
 
4.1 Investigational product/treatment 
Sildenafil 25 mg or look-alike placebo tablets three times daily orally from randomization 
until delivery or 32 weeks gestation. 
4.2 Use of co-intervention 
Advice for rest, ultrasound fetal monitoring, delivery (cesarean section) for fetal indication 
if fetus deemed viable, corticosteroids for fetal lung maturation. 
4.3 Escape medication 
Not applicable.  
 
4.4 Other treatments      
 
     Indications for delivery: 
These criteria apply to all patients if any of the following conditions are met irrespective of 
the management based on randomised group (sildenafil or placebo): 
- CTG criteria: If an elevated pulsatility index exists, patients should have an Doppler 
ultrasound every 2 weeks. If the Doppler ultrasound shows absent or reversed EDF 
women should be admitted to hospital, corticosteroids should be administered and a 
CTG twice a day. STV (short-term variation) should be calculated daily from the CTG. 
The cut off „rescue‟ value of STV for delivering based on CTG at 26+0 to <29+0 
weeks is if STV <3,5 msec; and 29+0 to <32+0 weeks if STV < 4 msec. Or if, 
irrespective of STV, there are spontaneous repeated persistent unprovoked 
decelerations on CTG.  
- Umbilical artery Doppler criteria: Absolute indications for delivery in all randomised 
arms:  
o >32+0 weeks deliver if reversed umbilical artery EDF. 
o >34+0 weeks deliver if absent umbilical artery EDF.  
- Delivery may be undertaken according to local policies after 30+0 weeks if there is 
reversed umbilical artery EDF, and after 32+0 weeks if there is absent umbilical EDF.  
- Ductus venosus measurements can be used per local protocol for timing of delivery. 
- Maternal indication may also be an indication for delivery. 
 
Limits of fetal viability:  
In this study, performed by the 10 Perinatal Intensive Care Centers we consider an 
estimated fetal weight of ≥600 gram at ≥27 weeks of gestation the standard limits of fetal 
viability. In the period before either limit, individualized limits may be adapted, down to an 
estimated fetal weight of ≥500 gram at ≥26 weeks of gestation. This implicates a policy 
where clinicians abstain from delivery if fetuses are below this limit and the perceived 
chance of intact perinatal survival is very small.
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Doppler ultrasound is repeated at least every two weeks. Women with a fetus that is 
deemed viable according to gestational age and weight criteria are admitted for intensive 
fetal monitoring if Doppler ultrasound shows absent or reversed EDF women. 
Cardiotocography will be performed according to local protocol and will be used for timing 
of delivery. Criteria for intervention are: 
- Spontaneous repeated persistent unprovoked decelerations on CTG 
- Diminished short-term variation (STV) preferably calculated with computerized CTG 
(some decreased variation may be accepted in the period 24-72 hours after first 
corticosteroid administration). The cut off „rescue‟ value of STV for delivering based 
on CTG at 26+0 to <29+0 weeks is if STV <3,5 msec; and 29+0 to <32+0 weeks if 
STV < 4 msec.  
- Umbilical artery Doppler criteria: Absolute indications for delivery in all randomised 
arms:  
o >32+0 weeks deliver if reversed umbilical artery EDF. 
o >34+0 weeks deliver if absent umbilical artery EDF. 
 
- Ductus venosus measurements can be used per local protocol for timing of delivery. 
- Maternal indication may also be an indication for delivery. 
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6. INVESTIGATIONAL PRODUCT  
 
6.1.Name and description of investigational  product(s) 
Sildenafil 25 mg (as citrate) tablets and placebo tablets for oral administration will be 
produced by Tiofarma according to GMP. The placebo tablets will have identical appearance 
as the sildenafil tablets More detailed description about the IMP will be provided in the IMPD.  
 
 
6.2 Summary of findings from non-clinical studies 
There was one systematic review of the literature in 2007.[2] This review described studies 
evaluating the effects of sildenafil on uterine vessels or myometrium either in vitro or in 
experimental animal models, as well as clinical trials and case reports on the outcome of 
pregnant women treated with sildenafil. The information was obtained from: three in vitro 
studies, five studies performed in experimental animal models, four studies on women with 
fertility and sterility disorders receiving 100 mg/day of sildenafil intravaginally, and two case 
reports of pregnant women who received sildenafil for the treatment of pulmonary 
hypertension. Incubation with sildenafil of different in vitro preparations resulted in vasodilator 
and uterine relaxant effects. No evidence of teratogenicity was observed in the studies 
performed in mice, rats and dogs. Sildenafil increased fetal weight in rats. In women, 
contradictory results on uterine blood flow and endometrial development were reported after 
the intravaginal administration of sildenafil. No adverse fetal outcomes were reported in the 
two pregnant women with pulmonary hypertension receiving sildenafil late in their pregnancy.  
 
After 2007, 21 more studies have been published that were identified in the present search. 
There were 11 experimental animal model studies. One study showed 1.5 times more body 
weight gain in the offspring of guinea pigs exposed to sildenafil during gestation, and favored 
fetal tolerability to induced intrapartum asphyxia.[3] In another study of healthy Sprague-
Dawley rats sildenafil had no effect on pup number and size.[4]This was also not the case in 
a study in L-NAME treated Sprague-Dawley rats.[5] A fourth study in healthy pregnant Wistar 
rats showed increased fetal size, but no decreased survival rates.[6] In a fifth study, a pre-
eclampsia model of L-NAME treated Sprague-Dawley rats, sildenafil reduced the plasma 
levels of anti-angiogenic factors involved in the maternal syndrome of placental 
insufficiency.[7] The next study demonstrated improved endothelial function in L-NAME 
treated Wistar rats, a rat pre-eclampsia model.[8] In another study, sildenafil citrate treatment 
dose-dependently increased fetal weight in an ovine model.[9] In contrast, in a single 
umbilical artery ligation sheep model of growth restriction, there was no positive effect of 
sildenafil.[10] In a Wistar pregnant rat pre-eclampsia model sildenafil improved uterine artery 
blood flow and fetal weight gain and increased survival rates without fetotoxic effects, and 
reversed maternal hypertension and proteinuria.[11] Moreover, the offspring from these 
sildenafil-treated rat mothers had normalised learning ability.[12] Finally, in a mouse model of 
pre-eclampsia (a catecholamine knock-out model) abnormal fetal weight normalized and 
abnormal umbilical Doppler waveforms improved after sildenafil treatment.[13] 
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There were 4 new human in vitro studies of vasoactivity. One older study (already in the 
2007 review) showed increased myometrial small artery vasoconstriction and decreased 
endothelium-dependent vasodilatation in small vessels taken at delivery from women with 
versus without fetal growth restriction, which was significantly antagonized by sildenafil 
administration.[14] Two other similar studies in women with pre-eclampsia versus controls 
failed to demonstrate this effect.[15, 16] In another study, it was shown that sildenafil evoked 
relaxation responses in the umbilical arteries from neonates born from preeclamptic mothers 
that were almost similar to the responses in umbilical arteries from a normal pregnancy.[17] 
A similar study in arteries dissected from placentas of normal pregnancies, sildenafil citrate 
produced dose dependent vasodilatation.[18] 
 
For more detailed information about the registered product, see attachment SPC Viagra.  
 
6.3 Summary of findings from clinical studies 
There were two studies of pharmacokinetics and safety profiles. One study showed rapid 
clearance of the drug in neonates having been administered sildenafil for persistant 
pulmonary hypertension, but a longer half-life in neonates compared to adult controls.[19] 
There were no increased ocular complications from sildenafil administration.[20] 
There are two clinical studies, one randomized clinical trial (RCT) in preeclampsia, and one 
cohort study in fetal growth restriction. The RCT was a small study of sildenafil citrate (doses 
20-40-80 mg three times daily) versus placebo in 35 women with preeclampsia at gestational 
ages 24-34 weeks. The drug was well tolerated with no increase in maternal or fetal adverse 
outcomes, but without beneficial effects in this population.[16]The cohort study was in 
women with severe fetal growth restriction below 25 weeks or 600 grams and dismal 
prognosis. Women were offered sildenafil 25mg three times daily until delivery. Those who 
were actually treated (n=10) were compared with controls (n=17). Fetal estimated growth 
improved significantly more often in treated patients, and there was a non-significant trend 
towards improvement in intact survival: 50% versus 29% (study underpowered for this 
outcome).[1] Finally, there was one case report showing resolution of high uterine artery 
pulsatility index and notching following sildenafil citrate treatment in a growth-restricted 26 
week pregnancy, that went on to delivery at 33 weeks.[21] 
For more detailed information about the registered product, see attachment SPC Viagra.  
 
6.4 Summary of known and potential risks and benefits 
For more detailed information about the registered product, see attachment SPC Viagra. 
Known side effects of Sildenafil are: headache, blushing, dyspepsia, visual disturbances, 
stuffy nose, dizziness and disturbances in color vision.  
 There are major cardiovascular events associated with the use of sildenafil. There is also 
a recent suggestion of an association of sildenafil use with melanoma development. [22] All 
major events are very unlikely to be of any significance in this patient group and the perinatal 
risks of the pathological process under study far outweigh the theoretical risks. Of course, 
patients in the study will be closely monitored for these outcomes. 
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6.5 Description and justification of route of administration and dosage 
For more detailed information about the registered product, see attachment SPC Viagra.  
Our understanding is that there is no evidence of using Sildenafil in pregnancy and 
therefore no experience in term of dose range but Sildenafil doses already used for 
pulmonary hypertension in neonates and young children are much smaller than 25mg (25-
500micrograms per kg of body weight).  
The choice for the dosage of 25 mg three times a day is based on the existing research 
on sildenafil in IUGR. Von Dadelszen et al [1] used 25 mg three times daily as intervention 
and showed increased AC growth compared with sildenafil naïve patients. Samangaya et al 
[16] concluded that Sildenafil in the escalating dose regimen 20–80 mg three times daily was 
well tolerated, with no increase in maternal or fetal morbidity or mortality but did not prolong 
pregnancy duration in women with preeclampsia. 
 
6.6 Dosages, dosage modifications and method of administration 
For more detailed information about the registered product, see attachment SPC Viagra. 
 
6.7 Preparation and labelling of Investigational Medicinal Product 
Sildenafil and placebo tablets will be produced by Tiofarma B.V. Information about the 
composition and production will be provided in the Investigational Medicinal Product Dossier 
(IMPD). The bottles containing 90 tablets sildenafil (as citrate) or placebo will be produced 
and labeled as IMP in compliance with GMP and other applicable regulatory requirements.  
The sponsor will arrange delivery of  sildenafil and placebo to the trial sites. No 
investigational medicinal product will be shipped until the sponsor has verified that all 
regulatory required documents and approvals for the site are available. 
The investigational medicinal product should be stored according to the information provided 
on the label and in such a manner that accidental loss or destruction or access by an 
unauthorized person is prevented.  
  
6.8 Drug accountability 
The investigator, or a pharmacist or other appropriate individual who is designated by the 
investigator, should maintain records of the product‟s delivery to the trial site, the inventory at 
the site, the use by each patient, and the return to the sponsor or alternative disposition of 
unused product(s). These records should include dates, quantities, lot numbers, expiration 
dates and patient study identification (if applicable). Investigators should maintain records 
that document adequately that the patients were provided the doses specified by the protocol 
and reconcile all investigational product(s) received from the sponsor 
Partially used investigational medicinal product should not be redispensed to either the same 
or another patient after it has been returned. 
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The trial site should destroy used or partially used study drug containers after drug 
accountability records have been completed. Destruction should be documented. 
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7. NON-INVESTIGATIONAL PRODUCT 
 
N/A 
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8. METHODS 
8.1 Study parameters/endpoints 
8.1.1. Main study parameter/endpoint 
Intact neonatal survival until term age 
8.1.2. Secondary study parameters/endpoints (if applicable) 
1) to evaluate whether Sildenafil citrate, compared to placebo, increases the 
likelihood of improved fetal growth velocity assessed by ultrasound abdominal 
circumference measurements (AC);  
2) to evaluate whether Sildenafil citrate, compared to placebo, increases the 
likelihood of age-adequate performance on the two-year Bayley scales of infant 
development (BSID)-III (composite cognitive score and composite motor score); 
3) to assess co-incidence and severity of the maternal syndrome of pre-eclampsia / 
HELLP-syndrome  
8.1.3. Other study parameters (if applicable) 
Fetal Doppler studies, PlGF point-of-care assessment 
  
8.2 Randomisation, blinding and treatment allocation 
Randomisation will be centrally controlled using an on-line computerised randomisation 
service.  Centres will be able to access the randomisation service 24hr/day. Masking to 
the next allocated treatment will be achieved by central randomisation and random block 
sizes of 2 to 6. The trial will be double-blinded and placebo-controlled. Subjects will be 
randomized in a 1:1 ratio to study medication (Sildenafil citrate) and placebo.  
Randomisation will be stratified by centre (to prevent any imbalance between groups in 
aspects of maternal or neonatal care that may differ between centres). All personnel, 
except for the pharmacist, and the patient will remain blinded to the treatment being 
received. In case of SUSAR‟s the randomisation code could be broken prematurely, for 
cessation of the intervention drug (sildenafil or placebo) will be adequate. 
 
8.3 Study procedures 
The intervention will be oral Sildenafil citrate 25mg tid.  Study medication (Viagra® or 
indistinguishable placebo tablets, produced and supplied by Tiofarma) will be taken 3 
times daily from randomization until delivery (maximum 32 weeks). 
 
MANAGEMENT  
Co-interventions will be documented: fetal surveillance, lifestyle modification, 
betamethasone for fetal lung maturation (once gestational age and/or EFW deemed 
appropriate by treating clinicians), detection of superimposed pre-eclampsia, MgSO4 for 
perinatal neuroprotection, and delivery (indication, timing, and route). The STRIDER Trial 
protocol allows centres to provide their usual „real-world‟ care.   
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All women with severe growth restriction (also those who do not participate) will receive 
increased fetal and maternal surveillance according to local protocols, consisting of fetal 
ultrasound surveillance at randomisation, 2 days, 5 days, 10 days and 14 days after 
recruitment; and subsequently every 12-16 days below viability limits; every 6-8 days 
beyond viability limits. Ultrasound surveillance will include umbilical artery, middle cerebral 
artery, ductus venosus and aortic isthmus Doppler indices; fetal biometry; amniotic fluid 
index; deepest vertical amniotic fluid pocket.  Fetal surveillance for current fetal condition 
will be with computerised CTG (depending on unit practice; only at and beyond the limits 
of viability), timed depending on ultrasound findings and admission status.  
 
Standard maternal surveillance will include, at least, the measurement of blood pressure, 
proteinuria (dipstick and random protein:creatinine ratio), pulse oximetry, complete blood 
count, creatinine, uric acid, aspartate transaminase, bilirubin, and albumin. In addition 
experimental biochemical markers of placental function will be taken alongside this trial 
and stored. Tests will be repeated at least every 12-16 days in outpatients and every 6-8 
days in inpatients. 
 
BP management decisions should not be made based on home BP measurements alone.  
Clinicians should treat hypertension with labetalol, nifedipine or methyldopa, as reflected 
in national and international guidelines. The following must not be used: atenolol (which 
may impair intrauterine fetal growth), or ACE inhibitors, angiotensin receptor antagonists, 
or direct renin inhibitors (which are or are presumed to be fetotoxic). Sildenafil, itself an 
effective antihypertensive agent in pregnancy, is not a contraindication for other 
antihypertensive use, but management should be adjusted according to observed effects. 
 
There is no standard of care for many obstetric interventions. As such, the STRIDER Trial 
protocol allows centres to provide their usual form of care. This may involve differential 
monitoring which will reflect the way the treatments would be applied in normal clinical 
practice. However, randomisation is stratified by center and data are collected on potential 
co-interventions (e.g., bed rest, hospitalisation, and antihypertensives [other than 
Sildenafil]) and their impact on outcome will be examined by secondary analyses. No 
special restrictions will apply with regards to diet, activities or other lifestyle items, unless 
so indicated by the treating physician. 
 
During data collection, data management teams, investigators, site personnel and 
subjects will remain blinded to whether women received the study medication or placebo 
throughout the entire study period.  
For the primary outcome a team of observers will jointly review the charts for consensus 
on the presence or absence of the outcomes. Severe central nervous system (CNS) injury 
(diagnosed by ultrasound and/or magnetic resonance imaging [MRI]) is defined by 
periventricular leukomalacia (PVL) grade II or more or IntraCerebral Hemorrhage (ICH) 
grade III or more or Hydrocephalus. Non-CNS severe morbidity is defined by 
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bronchopulmonary dysplasia (BPD; the requirement of ambulatory oxygen therapy > 36 
weeks corrected gestational age), retinopathy of prematurity (ROP requiring treatment 
such as laser therapy; grade 2/3 or more), or necrotising enterocolitis (NEC; requiring 
surgery). This evaluation will also include focus on the detection of unexpected fetoxicity 
from sildenafil.  
 
For the secondary hypothesis - that Sildenafil citrate therapy increases the likelihood of 
increased growth velocity (measured by abdominal circumference [ultrasound]) for fetuses 
of pregnancies complicated by severe early-onset FGR -, fetal growth velocity will be 
defined as the average daily increase in ultrasound-estimated AC. The AC measured pre-
randomisation will be compared with the most recent informative measurement of the AC 
at least 12 days previously. AC measurements will be compared with the gestational age 
[in days since last menstrual period (LMP)] at which that measurement lies most closely to 
the 50th percentile. Therefore, should the interval between scans be 18 days, and AC 
have grown by the equivalent of 9 days, then the average daily growth will be 0.5. 
 
For the specific secondary hypothesis - that Sildenafil citrate therapy increases the 
likelihood of age-adequate performance (both MDI [Mental Developmental Index] and PDI 
[Psychomotor Developmental Index] >85) on the two-year Bayley scales of infant 
development (BSID)-III - children will be seen and tested at two years by trained 
paediatric psychologists. This will also be tested with the Bayley scores of both groups as 
continuous measures, to test if a clinically significant difference is present (>7 points 
difference between groups, i.e. ½ standard deviation). The study will have sufficient power 
for these outcomes. Also, neurological development will be tested for CP (cerebral palsy) 
rate including severity scaling with Gross Motor Function Classification Scale (GMFCS) 
and a CBCL-questionnaire (Child Behaviour CheckList) will be administered. Difference in 
incidence of head circumference <-1 SDS will also be tested.  
 
There will be planned subgroup analyses for differential effects to evaluate the effect of 
Sildenafil on the abovementioned outcome measures in subgroups defined by a) an 
abnormal or normal serum level of placental growth factor (PlGF); b) other patient 
characteristics available at baseline such as gestational age, estimated fetal weight; 
 
It is the intention (outside the scope of this proposal subject to secondary evaluation by 
the ethics committee) to perform several additional studies in this complex patient group. 
Firstly, paediatric follow-up according to the Dutch National protocol at five years 
(including IQ, CBCL, movement-ABC, and pediatric check-up). Secondly, 
pathophysiological MRI-studies regarding the development of white matter damage in 
children, and the association between volumetric studies at 36-40 weeks corrected 
gestational age and long-term outcomes. Both studies will also include focus on the 
detection of unlikely fetoxicity from sildenafil. Thirdly, fundamental research on biomedical 
diagnostic tools protein, RNA-markers, epigenetic changes, for example longitudinal PlGF 
protein levels, or plasma RNA-markers (CSH1, GH1, ADAM12). These are promising 
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biochemical markers of placental insufficiency (among which PlGF) that will be tested 
alongside this trial. Analysis will be performed after closure of the trial for prediction on 
fetal outcome, placental and fetal growth.  
 
Placenta(bed) investigations will be performed. In many cases a caesarean section will be 
the mode of delivery with the opportunity to take placentabed biopsies (uterine wall 
including vessels) after delivery of the placenta. Approximately 50% of these biopsies will 
contain spiral arteries (ref Veerbeek) in which sildenafil causes vasodilatation through the 
enhancement of the NO pathway (ref Wareing). Furthermore biopsies of basal plate and 
parenchyma of the placenta will be taken and processed for further analysis, such as 
methylation studies, immunologic cell subset analysis and vascular markers. After these 
fresh biopsies placenta will processed to be presented to the pathologist for standard 
investigations after  FGR. Results of the placenta investigations will be related to outcome 
and follow up. 
 
8.4 Withdrawal of individual subjects 
Subjects may withdraw at any time or be withdrawn by the investigator if the woman 
violates the study plan or for administrative and /or safety reasons. Patients who withdraw 
from the study will remain in their treatment group for the intent-to-treat analysis. Every 
effort will be made to obtain complete information on each patient randomized. The only 
reason for not obtaining complete information is that the patient was lost to follow up or 
that she withdraws consent to access her medical chart after delivery. Once a woman has 
been randomized, even though she stops taking the study medication for any reason, 
follow-up will be continued including the planned visits, maternal and fetal surveillance. If 
a woman refuses to complete her follow-up visits with the research nurse (RN), the RN 
will confirm permission to consult her hospital chart in order to be able to complete 
information on the primary outcome of the study. In this case, her data will be considered 
in the final analysis. If a woman stops the medication because of nausea, she will be 
encouraged to resume taking the medication as soon as she feels the nausea has 
subsided. 
8.4.1. Specific criteria for withdrawal (if applicable) 
Not applicable. 
 
8.5 Replacement of individual subjects after withdrawal 
Not applicable. 
 
8.6 Follow-up of subjects withdrawn from treatment 
If a woman refuses to complete her follow-up visits with the research nurse (RN), the RN 
will confirm permission to consult her hospital chart in order to be able to complete 
information on the primary outcome of the study. In this case, her data will be considered 
in the final analysis. 
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8.7Premature termination of the study 
The DSMB can decide to terminate the study prematurely in case of safety concerns. The 
DSMB can decide to terminate the study prematurely in case the interim analysis shows 
clear benefit or harm of either one of the treatments (sildenafil or placebo) or due to external 
evidence. One interim analysis will be performed after 177 cases, with p < .01. 
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9. SAFETY REPORTING 
9.1 Section 10 WMO event 
In accordance to section 10, subsection 4, of the WMO, the sponsor will suspend the 
study if there is sufficient ground that continuation of the study will jeopardise subject 
health or safety.  The sponsor will notify the accredited METC without undue delay of a 
temporary halt including the reason for such an action. The study will be suspended 
pending further review by the accredited METC. The investigator will take care that all 
subjects are kept informed. 
 
9.2 AEs, SAEs and SUSARs 
9.2.1. Adverse events (AEs) 
Adverse events are defined as any undesirable experience occurring to a subject 
during the study, whether or not considered related to sildenafil. All adverse events 
reported spontaneously by the subject or observed by the investigator or his staff will 
be recorded. 
 
9.2.2 Serious adverse events (SAEs) 
A serious adverse event is any untoward medical occurrence or effect that at any 
dose:  
- results in death; 
- is life threatening (at the time of the event); 
- requires hospitalisation or prolongation of existing inpatients‟ hospitalisation; 
- results in persistent or significant disability or incapacity; 
- is a congenital anomaly or birth defect; 
- Any other important medical event that may not result in death, be life threatening, 
or require hospitalization, may be considered a serious adverse experience when, 
based upon appropriate medical judgement, the event may jeopardize the subject 
or may require an intervention to prevent one of the outcomes listed above. 
 
Whether or not related to the study medication, any SAE which occurs to patients 
from the time the consent is signed through 30 days after completion of the study 
must be reported within 24 hours to one of the individual(s) listed on the Contact 
Information Sheet, the Principal Investigator of the study. The DSMB should be 
informed after each 3 SAEs.  
The sponsor will report the SAEs through the web portal ToetsingOnline to the 
accredited METC that approved the protocol, within 15 days after the sponsor has 
first knowledge of the serious adverse reactions. Context specific SAEs (specified in 
paragraph 9.2.3) will not be reported for each individual case through the web portal 
ToetsingOnline. Context specific SAEs will be reported to the DSMB by line listing 
after completion of the study by each 50 participants. Context specific SAEs will be 
reported to the METC by line listing yearly.  
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Non context-specific SAEs that result in death or are life threatening should be 
reported expedited through the web portal ToetsingOnline. The expedited reporting 
will occur not later than 7 days after the responsible investigator has first knowledge 
of the adverse reaction. This is for a preliminary report with another 8 days for 
completion of the report.  
 
9.2.3 Context-specific SAE reporting 
 
This study population (possibly critically ill preterm infants) has a high risk of serious 
complications (so-called “context-specific SAE‟s”), which are inherent to their vulnerable 
condition and unrelated to the intervention which is under evaluation in this trial.  
These complications are included in the primary and secondary outcomes of this study and 
are recorded in the Case Report Form. This documentation will include the 
classification/gradation of the complication, type of action taken if appropriate (with some 
complications a wait and see approach is warranted).  
In light of the above, immediate and individual reporting of all these condition related 
complications will not enhance the safety of study. Therefore we will report only maternal 
SAEs and fetal or neonatal death immediately through toetsingonline. The DSMB should be 
informed after each 3 non context-specific SAEs, including fetal or neonatal death. The 
neonatal context-specific SAEs will be reported at on beforehand determined evaluation 
moments of DSMB, after completion of the study by each 50 participants. 
The context-specific SAEs that will be identified include the following events: 
 Maternal hospital admission for observation and delivery 
 Maternal hypertensive disorder 
 NICU admission 
 RDS requiring surfactant/BPD 
 Persistent pulmonary hypertension of the newborn requiring inhalation NO.  
 Mechanical ventilation, requiring postnatal steroids 
 Supplemental oxygen 
 Hypo- or hypertension 
 Hyperglycaemia requiring the use of insulin therapy 
 Nosocomial infection, like sepsis, meningitis and pneumonia 
 Pulmonary hemorrhage, pneumothorax and pulmonary interstitial emphysema 
 Hemodynamic significant patent ductus arteriosus for which medical intervention or 
surgical ligation is needed 
 Necrotising enterocolitis (NEC), diagnosed at surgery, autopsy or by radiographic 
finding of pneumotosis intestinalis or hepatobiliary gas (Bell stage II) 
 Gastrointestinal bleeding 
 Isolated gastrointestinal perforation diagnosed on abdominal radiography 
 Intraventricular haemorrhage (IVH) and/or periventricular leucomalacia (PVL), 
including grading on cerebral ultrasonography according to protocol defined by Ment 
et.al. [23]  
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 Retinopathy of prematurity, including grading following international classification 
 
9.2.4 Suspected unexpected serious adverse reactions (SUSARs) 
Adverse reactions are all untoward and unintended responses to an investigational 
product related to any dose administered. 
 
Unexpected adverse reactions are SUSARs if the following three conditions are met: 
1. the event must be serious (see chapter 9.2.2); 
2. there must be a certain degree of probability that the event is a harmful and an 
undesirable reaction to the medicinal product under investigation, regardless of 
the administered dose; 
3. the adverse reaction must be unexpected, that is to say, the nature and severity 
of the adverse reaction are not in agreement with the product information as 
recorded in: 
- Summary of Product Characteristics (SPC) for an authorised medicinal 
product; 
- Investigator‟s Brochure for an unauthorised medicinal product. 
 
The sponsor will report expedited the following SUSARs through the web portal 
ToetsingOnline to the METC: 
 SUSARs that have arisen in the clinical trial that was assessed by the METC; 
 SUSARs that have arisen in other clinical trials of the same sponsor and with the 
same medicinal product, and that could have consequences for the safety of the 
subjects involved in the clinical trial that was assessed by the METC. 
The remaining SUSARs are recorded in an overview list (line-listing) that will be 
submitted once every half year to the METC. This line-listing provides an overview 
of all SUSARs from the study medicine, accompanied by a brief report highlighting 
the main points of concern.  
The expedited reporting of SUSARs through the web portal ToetsingOnline is 
sufficient as notification to the competent authority. 
 
The sponsor will report expedited all SUSARs to the competent authorities in other 
Member States, according to the requirements of the Member States.  
 
The expedited reporting will occur not later than 15 days after the sponsor has first 
knowledge of the adverse reactions. For fatal or life threatening cases the term will 
be maximal 7 days for a preliminary report with another 8 days for completion of the 
report.  
 
Whether or not related to the study medication, any SUSAR which occurs to patients 
from the time the consent is signed through 30 days after completion of the study 
must be reported within 24 hours to one of the individual(s) listed on the Contact 
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Information Sheet, the Principal Investigator of the study and then the DSMB should 
be immediately informed. All subjects with SUSAR must be followed-up for outcome 
by the DSMB. 
 
 
9.3 Annual safety report 
 
In addition to the expedited reporting of SUSARs, the sponsor will submit, once a year 
throughout the clinical trial, a safety report to the accredited METC, competent authority, 
and competent authorities of the concerned Member States. 
This safety report consists of: 
 a list of all suspected (unexpected or expected) serious adverse reactions, along with 
an aggregated summary table of all reported serious adverse reactions, ordered by 
organ system, per study; 
 a report concerning the safety of the subjects, consisting of a complete safety analysis 
and an evaluation of the balance between the efficacy and the harmfulness of the 
medicine under investigation. 
 
9.4 Follow-up of adverse events 
All AEs will be followed until they have abated, or until a stable situation has been 
reached. Depending on the event, follow up may require additional tests or medical 
procedures as indicated, and/or referral to the general physician or a medical specialist. 
SAEs need to be reported till end of study within the Netherlands, as defined in the 
protocol  
 
9.5 Data Safety Monitoring Board (DSMB) / Safety Committee 
Data Safety Monitoring Board (DSMB) that will be called upon to monitor compliance and 
cross-over, and review any unexpected adverse events. The DSMB will include prof. dr. 
J.G.P. Tijssen, MD, PhD - statistician (chair), prof. dr. F.M. Helmerhorst, MD, PhD – 
gynaecologist LUMC, prof. dr. M.P.M. Burger, MD, PhD – gynaecologist AMC, dr. J.H. 
van der Lee, MD, PhD – epidemiologist AMC, dr D.P. van der Ham – gynaecologist 
Martini Ziekenhuis and dr. T.R. de Haan, MD, PhD – neonatologist AMC.  
The DSMB will meet as required, by teleconference, to review any unexpected adverse 
events. The DSMB has the right to review any variables that may have an impact on the 
trial.  
 
One interim analysis on safety parameters (neonatal mortality and morbidity) will be 
performed for the first 177 cases, with a p <.01. Interim analysis will be done after 177 
deliveries.  
 
The advice(s) of the DSMB will only be sent to the sponsor of the study. Should the 
sponsor decide not to fully implement the advice of the DSMB, the sponsor will send the 
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advice to the reviewing METC, including a note to substantiate why (part of) the advice of 
the DSMB will not be followed. 
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10. STATISTICAL ANALYSIS 
The University of British Columbia (UBC) will host data management. Through the 
UBC Perinatal Clinical Trials Unit data are collected. All data will be analysed on an 
intention-to-treat basis: that is, for the purpose of analysis, all women will be included in 
the group to which they have been randomised. If women are lost to follow-up, they will 
be included in their randomised group for all outcomes for which we have information. 
Descriptive statistics will be calculated to check for major dissimilarities between study 
groups with respect to baseline information. Sensitivity analyses (including imputation 
strategies) will be performed to estimate the potential effects of missing data. 
 
Statistical analysis will be with Chi-square tests (two-sided) and non-parametric Mann–
Whitney tests, where appropriate, using the latest version of SPSS (SPSS Chicago, 
Illinois, USA). The null hypothesis assumes equivalence in the primary outcome. 
Subgroup analysis for the effect of low PlGF at inclusion, abnormal fetal Dopplers at 
inclusion, and for the effect of other baseline parameters (gestational age, estimated fetal 
weight), and for participating centre on healthy survival will be performed. One interim 
analysis on safety parameters (neonatal mortality and morbidity) will be performed for the 
first 177 cases, with a p <.01. Interim analysis will be done after 177 deliveries.  
 
CONSORTIUM 
The logistics of the consortium studies, including this study, are taken care of by cluster 
coordinators and research nurses/midwives. Each cluster of medical centers in The 
Netherlands is linked to a perinatological center, of which the cluster coordinator is 
responsible for the logistics, data gathering, and data completion within that cluster. 
Research nurses/midwives inform all participating professionals about the ongoing 
studies within their medical center, are the contact persons for the participating patients 
and professionals, and perform the data entry of study data. The trial bureau of the 
consortium is responsible for the approval of the studies within the consortium at the 
medical ethical commissions of the participating hospitals. 
 
OUTCOME ASSESSMENT 
During data collection, data management teams, investigators, site personnel and 
subjects will remain blinded to whether women received the study medication or placebo 
throughout the entire study period.  
 
10.1 Primary study parameter(s) 
For the primary outcome a team of observers will jointly review the charts for consensus 
on the presence or absence of the outcomes. Severe central nervous system (CNS) 
injury (diagnosed by ultrasound and/or magnetic resonance imaging [MRI]) is defined by 
periventricular leukomalacia (PVL) grade II or more or IntraCerebral Hemorrhage (ICH) 
grade III or more or Hydrocephalus. Non-CNS severe morbidity is defined by 
bronchopulmonary dysplasia (BPD; the requirement of ambulatory oxygen therapy > 36 
weeks corrected gestational age), retinopathy of prematurity (ROP requiring treatment 
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such as laser therapy; grade 2/3 or more), or necrotising enterocolitis (NEC; requiring 
surgery). This evaluation will also include focus on the detection of unexpected fetoxicity 
from sildenafil.  
 
 
10.2 Secondary study parameter(s)  
For the secondary hypothesis - that Sildenafil citrate therapy increases the likelihood of 
increased growth velocity (measured by abdominal circumference [ultrasound]) for 
fetuses of pregnancies complicated by severe early-onset FGR -, fetal growth velocity will 
be defined as the average daily increase in ultrasound-estimated AC. The AC measured 
pre-randomisation will be compared with the most recent informative measurement of the 
AC at least 12 days previously. AC measurements will be compared with the gestational 
age [in days since last menstrual period (LMP)] at which that measurement lies most 
closely to the 50th percentile. Therefore, should the interval between scans be 18 days, 
and AC have grown by the equivalent of 9 days, then the average daily growth will be 0.5. 
 
For the specific secondary hypothesis - that Sildenafil citrate therapy increases the 
likelihood of age-adequate performance (both MDI [Mental Developmental Index] and PDI 
[Psychomotor Developmental Index] >85) on the two-year Bayley scales of infant 
development (BSID)-III - children will be seen and tested at two years by trained 
paediatric psychologists. This will also be tested with the Bayley scores of both groups as 
continuous measures, to test if a clinically significant difference is present (>7 points 
difference between groups, i.e. ½ standard deviation). The study will have sufficient 
power for these outcomes. Also, neurological development will be tested for CP (cerebral 
palsy) rate including severity scaling with Gross Motor Function Classification Scale 
(GMFCS) and a CBCL-questionnaire (Child Behaviour CheckList) will be administered. 
Difference in incidence of head circumference <-1 SDS will also be tested. 
 
10.3 Other study parameters 
There will be planned subgroup analyses for differential effects to evaluate the effect of 
Sildenafil on the abovementioned outcome measures in subgroups defined by a) an 
abnormal or normal serum level of placental growth factor (PlGF); b) other patient 
characteristics available at baseline such as gestational age, estimated fetal weight. 
 
It is the intention (outside the scope of this proposal) to perform several additional studies 
in this complex patient group. Firstly, paediatric follow-up according to the Dutch National 
protocol at five years (including IQ, CBCL, movement-ABC, and pediatric check-up). 
Secondly, pathophysiological MRI-studies regarding the development of white matter 
damage in children, and the association between volumetric studies at 36-40 weeks 
corrected gestational age and long-term outcomes. Both studies will also include focus on 
the detection of unlikely fetoxicity from sildenafil. Thirdly, fundamental research on 
biomedical diagnostic tools protein, RNA-markers, epigenetic changes, for example 
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longitudinal PlGF protein levels, or plasma RNA-markers (CSH1, GH1, ADAM12). These 
are promising biochemical markers of placental insufficiency (among which PlGF) that will 
be tested alongside this trial. Analysis will be performed after closure of the trial for 
prediction on fetal outcome, placental and fetal growth 
 
 
10.4 Interim analysis (if applicable) 
One interim analysis on safety parameters (neonatal mortality and morbidity) will be 
performed for the first 177 cases, with a p <.01. Interim analysis will be done after 177 
deliveries.  
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11. ETHICAL CONSIDERATIONS 
11.1 Regulation statement 
The study will be conducted according to the principles of the Declaration of Helsinki (see 
for the most recent version: www.wma.net) and in accordance with the Medical Research 
Involving Human Subjects Act (WMO) and other guidelines, regulations and Acts. 
 
11.2 Recruitment and consent 
Women are referred to the 10 perinatal tertiary care centers, as part of routine care. After 
establishing eligibility, women and their partners will be counselled by the supervising 
doctor or by the venter-appointed research midwife/nurse. They will also receive written 
information (see appendices). They will have ample time (1-7 days) to consider their 
decision.   
 
11.3 Objection by minors or incapacitated subjects (if applicable) 
Not applicable. 
 
11.4 Benefits and risks assessment, group relatedness 
The expected/potential benefit for participants is the hypothesis that sildenafil improves 
the intact neonatal survival until term age and increases the likelihood of increased growth 
velocity (measured by abdominal circumference [ultrasound]) for fetuses. 
Participants could experience side effects of the study medication. Known side effects of 
Sildenafil are described in section 12.1. There are no other specific risks for participants. 
 
11.5 Compensation for injury 
 
The sponsor/investigator has a liability insurance which is in accordance with article 7, 
subsection 6 of the WMO. 
  
The sponsor (also) has an insurance which is in accordance with the legal requirements 
in the Netherlands (Article 7 WMO and the Measure regarding Compulsory Insurance for 
Clinical Research in Humans of 23th June 2003). This insurance provides cover for 
damage to research subjects through injury or death caused by the study. 
1. € 450.000,-- (i.e. four hundred and fifty thousand Euro) for death or injury for each 
subject who participates in the Research; 
2. € 3.500.000,-- (i.e. three million five hundred thousand Euro) for death or injury for 
all subjects who participate in the Research;  
3. € 5.000.000,-- (i.e. five million Euro) for the total damage incurred by the 
organisation for all damage disclosed by scientific research for the Sponsor as 
„verrichter‟ in the meaning of said Act in each year of insurance coverage. 
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The insurance applies to the damage that becomes apparent during the study or within 4 
years after the end of the study. 
 
11.6 Incentives (if applicable) 
Not applicable. 
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12. ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION 
 
12.1 Handling and storage of data and documents 
The patients will receive a unique code, based on the order they have been included in 
the study. This code will be anonymous and not be based on name or date of birth of the 
patient.  
The CRF will be electronical and the persons who will have access to the data are: the 
study coordinator, the study investigator and the study nurse. 
 
12.2 Monitoring and Quality Assurance  
Dr. J.J.H. Bakker will monitor the data of the study. The monitoring will consist of one visit 
before the start of the trial. During the trial visits will be yearly. One visit will take place 
after closing of the study.  
 
12.3 Amendments  
 
A „substantial amendment‟ is defined as an amendment to the terms of the METC 
application, or to the protocol or any other supporting documentation, that is likely to 
affect to a significant degree: 
- the safety or physical or mental integrity of the subjects of the trial; 
- the scientific value of the trial; 
- the conduct or management of the trial; or 
- the quality or safety of any intervention used in the trial. 
 
All substantial amendments will be notified to the METC and to the competent authority. 
 
Non-substantial amendments will not be notified to the accredited METC and the 
competent authority, but will be recorded and filed by the sponsor.  
 
12.4 Annual progress report 
The sponsor/investigator will submit a summary of the progress of the trial to the 
accredited METC once a year. Information will be provided on the date of inclusion of the 
first subject, numbers of subjects included and numbers of subjects that have completed 
the trial, serious adverse events/ serious adverse reactions, other problems, and 
amendments.  
 
12.5 End of study report 
The sponsor will notify the accredited METC and the competent authority of the end of 
the study within a period of 90 days. The end of the study is defined as the last patient‟s 
last visit.  
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In case the study is ended prematurely, the sponsor will notify the accredited METC and 
the competent authority within 15 days, including the reasons for the premature 
termination. 
 
 Within one year after the end of the study, the investigator/sponsor will submit a final 
study report with the results of the study, including any publications/abstracts of the study, 
to the accredited METC and the Competent Authority. 
 
12.6 Public disclosure and publication policy 
 After completing the trial and data analysis, the results of the trial will be published   as 
soon as possible in an international journal on obstetrics. We aim publishing within 1 year 
after completing the trial. 
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13. STRUCTURED RISK ANALYSIS 
 
13.1 Potential issues of concern 
 
For product information, see the attached Summary of Product Characteristics.  
 
a. Level of knowledge about mechanism of action 
There is ample in vitro knowledge of the mechanism of action. This has been evidenced 
by in vitro mechanistic studies and in vivo pathophysiological studies. The in vivo studies 
have been both in animal models as well as human effect models. The specific test for the 
mechanism of action in the pregnant uterus with normal and abnormal uteroplacental 
circulation is limited and the reason for this study. The results of the field of sildenafil-
research however can be extrapolated to this setting.  
 
The mechanism of action of sildenafil is known for the indication of erectile dysfunction: 
 
Sildenafil is an oral therapy for erectile dysfunction. In the natural setting, i.e. with sexual 
stimulation, it restores impaired erectile function by increasing blood flow to the penis. 
The physiological mechanism responsible for erection of the penis involves the release of 
nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide then 
activates the enzyme guanylate cyclase, which results in increased levels of cyclic 
guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus 
cavernosum and allowing inflow of blood. Sildenafil is a potent and selective inhibitor of 
cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 
is responsible for degradation of cGMP. Sildenafil has a peripheral site of action on 
erections. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum 
but potently enhances the relaxant effect of NO on this tissue. When the NO/cGMP 
pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil 
results in increased corpus cavernosum levels of cGMP. Therefore sexual stimulation is 
required in order for sildenafil to produce its intended beneficial pharmacological effects. 
 
Studies in vitro have shown that sildenafil is selective for PDE5, which is involved in the 
erection process. Its effect is more potent on PDE5 than on other known 
phosphodiesterases. There is a 10-fold selectivity over PDE6 which is involved in the 
phototransduction pathway in the retina. At maximum recommended doses, there is an 
80-fold selectivity over PDE1, and over 700-fold over PDE2, 3, 4, 7, 8, 9, 10 and 11. In 
particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the 
cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility. 
 
b. Previous exposure of human beings with the test product(s) and/or products with a 
similar biological mechanism 
There are numerous reports of the use of the drug sildenafil for different indications. There 
are sufficient reports of exposure of pregnant women and their fetuses to sildenafil, being 
given for another indication, without knowledgeable side-effects. The information of use of 
sildenafil in this population is scarce and the reason for this study 
 
c. Can the primary or secondary mechanism be induced in animals and/or in ex-vivo 
human cell material? 
No.  
 
d. Selectivity of the mechanism to target tissue in animals and/or human beings 
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The mechanism of action is well-defined. Since the process that sildenafil influences is 
universal in the human system (smooth muscle relaxation) the drug is not selective for a 
specific organ but it is fairly selective for smooth muscle relaxation. 
 
e. Analysis of potential effect 
 Randomized controlled trial.  
 
f. Pharmacokinetic considerations 
Absorption 
Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached 
within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. The mean 
absolute oral bioavailability is 41% (range 25-63%). After oral dosing of sildenafil AUC and 
Cmax increase in proportion with dose over the recommended dose range (25-100 mg). 
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in 
tmax of 60 minutes and a mean reduction in Cmax of 29%. 
 
Distribution 
The mean steady state volume of distribution (Vd) for sildenafil is 105 l, indicating 
distribution into the tissues. After a single oral dose of 100 mg, the mean maximum total 
plasma concentration of sildenafil is approximately 440 ng/mL (CV 40%). Since sildenafil 
(and its major circulating 
N-desmethyl metabolite) is 96% bound to plasma proteins, this results in the mean 
maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM). Protein binding is 
independent of total drug concentrations. 
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% 
(average 188 ng) of the administered dose was present in ejaculate 90 minutes after 
dosing. 
 
Biotransformation 
Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor 
route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-
demethylation of sildenafil. 
This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in 
vitro potency for PDE5 approximately 50% that of the parent drug. Plasma concentrations 
of this metabolite are approximately 40% of those seen for sildenafil. The N-desmethyl 
metabolite is further metabolised, with a terminal half-life of approximately 4 h. 
 
Elimination 
The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half-life of 3-
5 h. After either oral or intravenous administration, sildenafil is excreted as metabolites 
predominantly in the faeces (approximately 80% of administered oral dose) and to a 
lesser extent in the urine (approximately 13% of administered oral dose). 
 
Pharmacokinetics in special patient groups 
 
Elderly 
Healthy, elderly volunteers (65 years or over) had a reduced clearance of sildenafil, 
resulting in approximately 90% higher plasma concentrations of sildenafil and the active 
N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 
years). Due to age-differences in plasma protein binding, the corresponding increase in 
free sildenafil plasma concentration was approximately 40%. 
 
Renal insufficiency 
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In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 
mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single 
oral dose. The mean AUC and Cmax of the N-desmethyl metabolite increased 126% and 
73% respectively, compared to age-matched volunteers with no renal impairment. 
However, due to high inter-subject variability, these differences were not statistically 
significant. In volunteers with severe renal impairment (creatinine clearance <30 mL/min), 
sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% 
and 88% respectively compared to age-matched volunteers with no renal impairment. In 
addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 
79% and 200% respectively. 
 
Hepatic insufficiency 
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil 
clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared 
to age-matched volunteers with no hepatic impairment. The pharmacokinetics of sildenafil 
in patients with severely impaired hepatic function have not been studied. 
 
g. Study population 
Women with a singleton pregnancy between 20 and 30 weeks with severe fetal growth 
restriction of likely placental origin, and with estimated significant likelihood of perinatal 
death. 
 
h. Interaction with other products 
- Effects of other medicinal products on sildenafil 
 
In vitro studies 
Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 
(major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may 
reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil 
clearance. 
 
In vivo studies 
Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil 
clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, 
erythromycin, cimetidine). 
Although no increased incidence of adverse events was observed in these patients, when 
sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25 mg 
should be considered. 
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 
inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted 
in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil 
plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 
ng/mL, compared to approximately 5 ng/ml when sildenafil was administered alone. This 
is consistent with ritonavir‟s marked effects on a broad range of P450 substrates. 
Sildenafil had no effect on ritonavir pharmacokinetics. Based on these pharmacokinetic 
results co-administration of sildenafil with ritonavir is not advised (see section 4.4) and in 
any event the maximum dose of sildenafil should under no circumstances exceed 25 mg 
within 48 hours. 
 
Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady 
state (1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140% 
increase in sildenafil Cmax and a 210% increase in sildenafil AUC. Sildenafil had no effect 
on saquinavir pharmacokinetics (see section 4.2). Stronger CYP3A4 inhibitors such as 
ketoconazole and itraconazole would be expected to have greater effects. 
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When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate 
CYP3A4 inhibitor, at steady state (500 mg twice daily. for 5 days), there was a 182% 
increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there 
was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, 
tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal 
circulating metabolite. Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific 
CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-
administered with sildenafil (50 mg) to healthy volunteers. 
 
Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to 
modest increases in plasma levels of sildenafil. 
Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the 
bioavailability of sildenafil. 
Although specific interaction studies were not conducted for all medicinal products, 
population pharmacokinetic analysis showed no effect of concomitant treatment on 
sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, 
warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, 
tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing 
diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-
adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, 
barbiturates). In a study of healthy male volunteers, co-administration of the endothelin 
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of 
CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg 
three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and Cmax, 
respectively. Therefore, concomitant administration of strong CYP3A4 inducers, such as 
rifampin, is expected to cause greater decreases in plasma concentrations of sildenafil. 
Nicorandil is a hybrid of potassium channel activator and nitrate. Due to the nitrate 
component it has the potential to result in a serious interaction with sildenafil. 
 
- Effects of sildenafil on other medicinal products 
 
In vitro studies 
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 
and 3A4 (IC50 > 150 μM). Given sildenafil peak plasma concentrations of approximately 1 
μM after recommended doses, it is unlikely that VIAGRA will alter the clearance of 
substrates of these isoenzymes. 
There are no data on the interaction of sildenafil and non-specific phosphodiesterase 
inhibitors such as theophylline or dipyridamole. 
 
In vivo studies 
Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), 
sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-
administration with nitric oxide donors or nitrates in any form is therefore contraindicated 
(see section 4.3 of SPC). 
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead 
to symptomatic hypotension in a few susceptible individuals. This is most likely to occur 
within 4 hours post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug 
interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 
mg, or 100 mg) were administered simultaneously to patients with benign prostatic 
hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean 
additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, 
and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 
4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were 
administered simultaneously to patients stabilized on doxazosin therapy, there were 
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infrequent reports of patients who experienced symptomatic postural hypotension. These 
reports included dizziness and light-headedness, but not syncope. 
No significant interactions were shown when sildenafil (50 mg) was co-administered with 
tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9. 
Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl 
salicylic acid (150 mg). 
 
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy 
volunteers with mean maximum blood alcohol levels of 80 mg/dl.  
Pooling of the following classes of antihypertensive medication: diuretics, beta-blockers, 
ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products 
(vasodilator and centrally-acting), adrenergic neurone blockers, calcium channel blockers 
and alpha-adrenoceptor blockers, showed no difference in the side effect profile in 
patients taking sildenafil compared to placebo treatment. In a specific interaction study, 
where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, 
there was an additional reduction on supine systolic blood pressure of 8 mmHg. The 
corresponding additional reduction in supine diastolic blood pressure was 7 mmHg. These 
additional blood pressure reductions were of a similar magnitude to those seen when 
sildenafil was administered alone to healthy volunteers (see section 5.1). 
Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease 
inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.  
In healthy male volunteers, sildenafil at steady state (80 mg t.i.d.) resulted in a 49.8% 
increase in bosentan AUC and a 42% increase in bosentan Cmax (125 mg b.i.d.). 
 
i. Predictability of effect 
 
j. Can effects be managed? 
 
k. Effects on the fetus 
Little research has been done to assess the effect of sildenafil on the fetus, while used 
during pregnancy. The existing literature states that, based on observational studies [24] 
and experimental animal studies [25] sildenafil does not appear to increase the risk of 
congenital malformations in exposed pregnancies and no embryo-fetal harm has been 
observed. Two recent case reports support this statement. [21, 26]  
Based on the existing literature we do not expect more severe adverse events than one 
would expect based on the natural course of the clinical situation and prognosis of this 
patient population. 
 
13.2 Synthesis 
There is ample in vitro knowledge of the mechanism of action of sildenafil. This has been 
evidenced by in vitro mechanistic studies and in vivo pathophysiological studies. The in 
vivo studies have been both in animal models as well as human effect models. The 
specific test for the mechanism of action in the pregnant uterus with normal and abnormal 
uteroplacental circulation is limited and the reason for this study. The results of the field of 
sildenafil-research however can be extrapolated to this setting.  
The risk for study participants is estimated as moderate.  
 
 
ZonMW 80-83600-98-20081 Dutch-STRIDER 
 
Version 7.0 12-2015  45 of 63 
14. Ancillary studies 
 
14.1 Questionnaires: Influence of Sildenafil on sexuality 
 
To monitor the influence of Sildenafil on sexuality of pregnant women, participants of 
the trial will be asked to complete a questionnaire on female sexuality: „McCoy 
Female Sexuality Questionnaire‟ (short version). This questionnaire consisting of nine 
questions about experiencing sexuality will be answered three times during 
participation of the study: at inclusion, after four weeks and after eight weeks. If 
participants are not using the study medication anymore or have delivered their baby, 
the second and/or third questionnaire will not be offered.  
The questionnaire is offered in the online program LimeSurvey, hosted by Clinical 
Research Unit in Academic Medical Hospital, Amsterdam. Participants of STRIDER 
study need to fill in a separate informed consent for the questionnaires. If a 
participant consents to participate in the questionnaires, she will receive a personal 
link to the LimeSurvey questionnaire so she can fill in the questionnaire at a time and 
place that is convenient for her.  
 
 
 
14.2 Evaluation of cardiac function 
 
Introduction  
Intrauterine growth restriction (IUGR) is associated with increased risk of perinatal 
complications and neonatal morbidity27. Epidemiological data have shown an 
association between IUGR and cardiovascular morbidity and mortality during 
adulthood, including increased rates of coronary heart disease, stroke, hypertension 
and non-insulin-dependent diabetes28-33.These findings support the existence of a 
maladaptive programming process in utero, whereby a stimulus or insult at a critical, 
sensitive period of early life has permanent effects on structure, physiology and 
metabolism32,34. In the case of IUGR the programming may result from adaptations to 
a condition where placental nutrient supply fails to match fetal demand. Recently 
compensatory feto-placental up-regulation of the nitric oxide system during fetal 
growth restriction (FGR) has been shown. These events are followed by nitric oxide 
pathway down-regulation postnatally, increasing susceptibility to cardiovascular 
disorders later in life32.  
Phosphodiesterase inhibition has been reported to cause placental vasodilation in 
pregnancies with FGR.  Sildenafil citrate works by inhibiting type 5 
phosphodiesterase (PDE5) which is responsible for the degradation of cGMP to 
guanosine monophosphate35. The inhibition of PDE5 delays the breakdown of cGMP 
and increases vasodilation36. During the Sildenafil Therapy In Dismal prognosis 
Early-onset intrauterine growth Restriction (STRIDER)37 study mothers with IUGR 
fetuses will be treated with sildenafil in an attempt to improve placental perfusion and 
thus fetal growth. This study allows for a unique opportunity to examine the cardiac 
function of IUGR fetuses and neonates and the cardiac effects of sildenafil on fetal 
and cardiac function in these individuals.  
Changes in cardiac function have been observed in both IUGR and small for 
gestational age (SGA) fetuses27,29,38,39-50. Changes in cardiac geometry have been 
reported in human fetuses and animal models. Cardiothoracic ratio and atrial areas 
were increased in the IUGR fetuses compared with control subjects. Left and right 
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sphericity indexes were decreased significantly in IUGR fetuses with thicker 
myocardial walls, when compared with control subjects38. The most probable 
pathophysiological mechanism for these changes is the increased myocardial 
workload in utero. Chronic intrauterine hypoxia results in increased placental vascular 
resistance, redistribution of cardiac output in favor of the left fetal heart, alterations of 
arterial structure (intima and medial thickening) and vascular tone regulation, and 
disturbances that contribute to the development of cardiac hypertrophy. The 
remodeling may be an adaptive response to the reduced substrate supply mediated 
through the modulation of specific gene expression at the myocardial level38.  
A few studies measuring cardiac function in IUGR fetuses using echocardiography 
have been performed. Both stroke volume (SV) and cardiac output (CO) have been 
shown to be increased in IUGR fetuses38. The use of M-mode and tissue Doppler 
imaging (TDI) has demonstrated a significantly reduced mitral annular-plane systolic 
excursion (MAPSE), tricuspid annular-plane systolic excursion (TAPSE), and S' in 
the IUGR fetuses compared with control subjects. Both the isovolumetric contraction 
time (IVCT) and ejection time (ET) were increased in the IUGR group. Diastolic 
function parameters also showed differences with decreased E' velocities and 
increased early/late trans-valvular filling velocities and E/E' ratios, isovolumetric 
relaxation time (IVRT), and E deceleration time in IUGR fetuses compared with 
control subjects38. The mean myocardial performance index (MPI) for the left 
ventricle was found to be significantly higher in IUGR fetuses with an abnormal 
umbilical artery (UA) Doppler compared to healthy fetuses45. The IUGR fetuses with 
the abnormal MPI also showed a significantly worse perinatal outcome and increased 
morbidity compared to those with a normal MPI (irrespective of the UA Doppler 
findings) and compared to the normal controles45. Another study showed that the MPI 
is raised in SGA fetuses before the arterial and venous Doppler abnormalities that 
characterize hypoxia are evident47. A higher left atrial pressure has been 
demonstrated in fetuses with IUGR, as indicated by the lower mobility of the septum 
primum, accompanied by higher ratios between early and late diastolic myocardial 
velocities on TDI. Placental dysfunction could be correlated to septal E'/A' ratios 
suggesting that this method could be useful to assess severity of placental 
dysfunction and fetal distress48. Fetal TDI is difficult however the use of the MAPSE 
and TAPSE can be useful as an alternative to evaluate fetal cardiac function40. In 
fetal echocardiography, M-mode longitudinal motion has previously been described 
as a feasible measurement with good reproducibility, and reference ranges have 
been published41.  
 
Changes in the cardiovascular system have also been observed in neonates and 
children who suffered IUGR or were SGA52-58. The fetal TAPSE, right sphericity 
index, IVRT, and cerebroplacental ratio have been shown to be strong predictors of 
postnatal vascular remodeling and infant hypertension38. Follow-up of SGA and 
IUGR fetuses into childhood showed that they had more globular hearts, reduced 
longitudinal motion, and impaired relaxation with an increase in radial function. Both 
groups showed increased blood pressure and carotid intima-media thickness. There 
was a linear tendency to worse cardiovascular results in IUGR as compared with 
SGA children41. SV, CO and left ventricular (LV) thickening were significantly 
increased in cases as compared with controls. Cases also showed a tendency to 
higher heart rate (HR) and LV ejection fraction. Longitudinal motion in systole was 
significantly reduced in IUGR group with a non-significant tendency to lower results in 
the SGA group. Both IUGR and SGA children showed signs of diastolic dysfunction, 
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mainly measured as an increase in E deceleration, decrease in diastolic annular 
velocities, and a tendency to higher IVRTs. There was a significant linear tendency to 
worse cardiac function in IUGR as compared with SGA children. 
  
Aim 
The purpose of this study is to: 
1) document the cardiac function of IUGR fetuses enrolled in the STRIDER study 
– is there evidence for cardiac dysfunction? 
2) document changes in cardiac function after starting sildenafil – is there a 
difference between before and after starting sildenafil and is there a difference 
between the treated and untreated fetuses? 
3) document postnatal cardiac function (including blood pressure) – is there a 
difference between the treated and untreated fetuses? 
 
Proposed Study:  
A prospective study of human fetal cardiac function in fetuses with IUGR pre and 
post maternal sildenafil therapy.                                                                                                 
Cardiac function will be evaluated using Doppler echocardiography before starting 
sildenafil therapy and one week thereafter, also patients receiving the placebo will 
undergo two echoes.  
A postnatal evaluation of cardiac function (including TDI) will also take place. 
Cardiac function will be determined as in the previous studies of Clur et al59-61 with 
the addition of the measurement of the isovolumetric contraction and relaxation times 
(IVCT, IVRT), MAPSE and TAPSE, excursion index of the septum primum (EISP) 
and aortic isthmus Doppler and pulsatility index (PI). The IVCT and IVRT will be 
expressed in milliseconds and as percentages of the cardiac cycle. The ductus 
venosus (DV), MCA, UA and hepatic artery Dopplers will also be recorded.  
 
Hypotheses:  
1) Cardiac dysfunction is present in fetuses with IUGR enrolled in the STRIDER 
study. 
2) Fetal cardiac dysfunction is improved by maternal intake of sildenafil in fetuses 
with IUGR.  
3) The fetal cardiac function of the treated fetuses is better than those treated with 
placebo.  
3) Neonatal cardiac function is better in those IUGR fetuses treated with sildenafil 
prenatally.  
 
Participating Centres: 
Academic Medical Center, Amsterdam; Leids Universitair Medisch Centrum, Leiden 
A separate informed consent will be asked to participants.  
Methods: 
Study population: 
30 fetuses included in the STRIDER study will be included. Of these fetuses at least 
one antepartum and one postpartum measurement should be available. 
Measurements: 
Fetal echocardiography will be performed according to standard recommendations62 
using the following equipment; Voluson E8 (GE Medical Systems, Milwaukee, WI, 
USA).  
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Recordings should be stored as uncompressed files and will all be reviewed by SAC 
who will also coordinate the data collection and database. 
Examinations will be performed by a fetal medicine specialists with experience in 
performing a fetal echocardiogram or a pediatric cardiologist (SAC). After confirming 
the cardiac anatomy, Doppler flow evaluation using the four-chamber and outflow-
tract views will be performed. To ensure the best repeatability and safety possible the 
following requirements will be strictly adhered to when making the measurements:  
1) Mechanical and thermal indices will be <1 throughout; 
2) A 3-mm pulse Doppler gate will be placed over the tricuspid valve (TV), mitral 
valve (MV) and pulmonary valve (PV) or positioned in the internal wall of the 
ascending aorta, close to the internal wall of the ascending aorta below the 
aortic valve (AoV), allowing concurrent display of the MV inflow and AoV 
outflow;  
3) As the time intervals for the RV cannot usually be measured simultaneously, 
we will include measurements of TV inflow and PV outflow with similar HRs 
and, where possible, recorded in a sweep from the TV towards the PV; 
4) Angle correction may be applied as appropriate up to a maximum of 15 
degrees over the valves;  
5) Sweep speed of 5 cm/s will be used, allowing for at least 4 consecutive heart 
beat registrations per recording; 
6) The Wall Motion Filter (WMF) will be set on 300 Hz37-65; 
7) Gain will be adjusted to an intermediate level so as to allow for the best 
visualization of thin closing valve clicks without loss of the Doppler flow 
images;  
8) The measurements will be made at the peaks of the clicks and not at the 
bases; 
9) The 2D measurements of the semilunar valves (mm) will be measured in 
systole and of the atrio-venrticular (AV)-valves in diastole (i.e. with the valves 
open), from hinge point to hinge point, and with the use of magnification. 
10)Sphericity Index: Ventricular base-to-apex lengths and transverse diameters 
will be measured on 2-dimentional images from an apical 4-chamber view at 
end-diastole. Ventricular sphericity indexes will be calculated as base-to-apex 
length/transverse diameter of the LV and RV, respectively66,67; 
11)MAPSE and TAPSE: will be measured by M-mode in real-time using a 2–6-
MHz linear curved-array transducer in an apical or basal four-chamber view, 
by placing the cursor at right angles to the AV junction, marked by the valve 
rings; mitral (medical) and tricuspid (lateral), respectively. The maximum 
amplitude of motion will be taken as the extent of displacement between end-
systole and end-diastole (measured in mm). For both measurements 
insonation by the ultrasound beam will be kept at an angle of <30 degrees
 
to 
the orientation of the ventricular wall or the interventricular septum, with no 
angle correction applied; 
12)EISP will be calculated as the ratio between the maximal excursion of the 
septum primum into the left atrium during diastole and the maximal diastolic 
diameter of the left atrium. Left and right atrial areas will be delineated on 2-
dimensional images from an apical or basal 4-chamber view at end-ventricular 
systole (maximum point of atrial distension)48; 
13)The cardiothoracic ratio was measured from a 4-chamber view, by the area 
method previously described(ref); 
14)The cerebroplacental ratio will be calculated by division of MCA and UA PI.  
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15)Ventricular end-diastolic septal and free wall thicknesses were measured by 
M-mode from a transverse 4-chamber view68. 
 
The following recordings will be made and stored for later analysis: 
1) Doppler over the TV and MV in 4-chamber view. 
2) Doppler recordings of MV and AoV in 5-chamber view. 
3) PV Doppler in the RV outflow-tract view. 
4) M-mode from a transverse 4-chamber view. 
5) MAPSE and TAPSE in 4-chamber view. 
6) Apical 4-chamber view at end systole (AV-valves open) and end-diastole (AV-
valves closed).  
7) The DV Doppler and PI. 
8) The MCA Doppler and PI. 
9) The UA Doppler and PI.  
10)Aortic isthmus Doppler and PI.  
11)The hepatic artery Doppler and PI. 
12)The Ductus Venosus Doppler and PI. 
 
 
Doppler flow over AV- and semilunar valves: – 
The following measurements will be made on the stored recordings:-  
Peak E-(early ventricular filling) and A-(atrial contraction) wave velocities (cm/s), E/A 
velocity ratio and time velocity integral (TVI) (cm) over the AV-valvess will be 
measured to assess diastolic function69,70.   
The time between AV-valve inflows (ms), semilunar valve ejection time (ms) and HR 
will be measured and used to calculate the MPI according to the formula a–b/b of Tei 
et al.74, where a=time between AV-valve inflow and b=the ejection time over the 
semilunar valve. MPI is a measure of global cardiac function incorporating the IVCT 
reflecting systolic function and the IVRT reflecting early diastolic function.  
The IVCT and IVRT will be measured and expressed in milliseconds and as a 
percentage of the cardiac cycle, e.g. IVCT 45 ms, IVRT 15ms. HR 150/min. One 
cardiac cycle is 400ms then IVCT is 11,25% of cardiac cycle. 
The presence or absence of AV-valve regurgitation will be noted. 
Systolic function will be expressed in terms of: peak velocity (m/s) and acceleration 
time (AT) (ms) over the semilunar valves, stroke volume (ml), cardiac output (ml/min), 
cardiac index (CO/kg), MAPSE/TAPSE and IVCT.  
The great vessel cross-sectional area (CSA) will be calculated using the formula 
CSA=(diameter/2)2. The diameter is the annulus of the valve. Stroke volume 
(SV)=TVI X CSA and cardiac output (CO)=SV X HR69,72. 
 
2)Venous flow patterns:  
DV flow patterns will be recorded by the fetal medicine specialist as previously 
described74. The sample volume will be kept as small as possible in order to avoid 
interferences from nearby vessels. The mean DV pulsatility index for the veins (PIV) 
will be calculated and evaluated according to published reference ranges74.  
 
3)Hepatic artery Doppler: HA flow patterns will be recorded by the fetal medicine 
specialist as previously described75. The PI and peak velocity will be recorded. 
 
In inter-observer and intra-observer reproducibility 
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Special attention to keep the reproducibility as high as possible will be made as 
mentioned above. All measurements will be digitally stored and analyzed by one 
observer. 
 
Outcome data will be collected from hospital notes/Astraia. A full postnatal 
echocardiogram will be performed on day 1 to 3 postapartum and day 7 to 10 
postpartum. A blood pressure will also be recorded postnatally.  
Outcome data on mortality and most relevant morbidity will be collected, mainly 
IRDS, dry lung, PPHN, chorioamnionitis, sepsis, NEC, BPD, IVH and ROP.  
 
Statistical analysis:       
Depending on the distribution of the measured values the student-t test, (normally 
distributed), or Mann-Whitney U test, (not normally distributed), using SPSS1876. A p 
value <0.05 will be considered statistically significant.  
 
 
 
14.3 The effect of antenatal Sildenafil in fetal growth restriction on neonatal renal 
oxygen saturation  
 
During fetal growth restriction (FGR) as a consequence of placental dysfunction, 
redistribution of the fetal blood circulation often occurs, favoring brain perfusion[77]. This 
compensatory mechanism may reverse after some time during chronic fetal hypoxia[78]. 
Long-term fetal hypoxia has shown in animal studies to eventually cause under 
vascularisation of the cerebral white matter[79]. This may account for the fact that infants 
born small for gestational age (SGA) shown delayed neurodevelopment growing up[80]. 
This intrauterine process of preferential blood flow to the brain may continue after birth[81]. 
Infants born after FGR have shown to have a higher cerebral tissue oxygen saturation and a 
lower fractional tissue oxygen extraction measured by near-infrared spectroscopy (NIRS), 
which may suggest increased cerebral perfusion, or decreased cerebral metabolism[82]. This 
phenomenon of increased cerebral oxygenation has also been seen in infants born after 
intrauterine exposure to maternal antihypertensive drugs, which often co-occurs with 
placental dysfunction and FGR[83]. 
Furthermore, both in SGA infants and in infants born after intrauterine exposure to 
antihypertensive drugs, a decreased oxygenation of the renal area has been observed, to 
simultaneously occur with the increased cerebral oxygenation. This has been expressed as 
an increased cerebro-renal oxygenation ratio (CROR)[81]. These recent findings suggest a 
continuous or recurrent compensational mechanism comparable to the intrauterine 
redistribution of blood and oxygen to the brain, also referred to as brain-sparing. Little is 
known about the clinical consequences of this phenomenon. 
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Near-infrared spectroscopy (NIRS) is a non-invasive, safe way to continuously assess tissue 
oxygen saturation. Tissue oxygen saturation reflects oxygen saturation of blood in three 
departments of the underlying tissue: arterial (estimated 25%), capillary (5%), en mainly 
venous blood (70%)[84]. Near-infrared light can penetrate tissue. Part of the light is then 
absorbed by hemoglobin (Hb) and another part with slightly different wavelength by 
oxygenated Hb (HbO2).  Due to the different absorption specters of Hb and HbO2 for near-
infrared light, the sensor detects the reflected light from two wavelengths, and the ratio of Hb 
and HbO2 can be calculated, which is the oxygen saturation of the underlying tissue (rSO2). 
By relating the fraction of tissue oxygen saturation of arterial oxygen saturation measured 
peripherally, the FTOE can be calculated (SpO2- rSO2) / SpO2. FTOE reflects the balance 
between oxygen delivery and consumption. Assuming oxygen consumption in the newborn 
brain remains relatively stable, FTOE reflects actual perfusion state of the brain[85].  
Though increasingly validated, the NIRS technique has still some uncertainties, lacking 
absolute precision and accuracy[86]. Also, different devices and sensors use various 
techniques and algorithms, hampering comparison. However, these differences have now 
mostly been established[87][88]. NIRS is most useful as trend monitor, but cerebral oxygen 
saturation values measured by NIRS of < 50% have been associated with cerebral 
damage[89, 90]. Furthermore, cerebral oxygen saturation values measured by NIRS have 
recently been shown to relate to neurodevelopmental outcome at two-three years of age, in 
preterm born infants[91]. NIRS for cerebral oxygenation measurements is currently 
increasingly being used as part of standard care for newborn infants admitted to the neonatal 
intensive care unit (NICU). All participating centers of this Strider sub study have already 
implemented cerebral oxygenation measurements using NIRS as part of standard care for 
newborn infants admitted to their NICU. 
 
Besides measuring cerebral oxygen saturation using NIRS, NIRS may also be a valuable 
method to assess systemic organ oxygenation. A decrease in systemic organ oxygenation 
may be an early sign for circulatory insufficiency, for systemic oxygenation may deteriorate 
prior to cerebral oxygenation in case of circulatory insufficiency, due to cerebrovascular 
autoregulation[92, 93]. This would make the continuous assessment of systemic organ 
perfusion clinically useful and is a focus of current research. Abdominal oxygenation 
measured by NIRS is strongly correlated to central venous oxygen saturation[94] and flow in 
the superior mesenteric artery, measured by Doppler[95]. Also, abdominal oxygen saturation 
is related to venous lactate measures[96], and to the occurrence of NEC[97]. All this 
circumstantial evidence by lack of golden standard for organ perfusion, supports the 
assumption that the NIRS technique can be used to assess systemic perfusion[98]. 
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Measurement of renal oxygen saturation by positioning the NIRS sensor in the flank region, 
has been validated mainly in infants with congenital heart defects. Furthermore, the CROR 
has previously been used as an indicator for the distribution of blood to either the brain or the 
lower body[81]. Finally, somatic (renal) NIRS measurements have shown to be feasible, safe 
and not distressing in the sick newborn infant, resulting in an increasing use in daily care[99]. 
 
Aim of this Strider sub study: 
To show an effect of the administration of Sildenafil to pregnant women with severe FGR on 
neonatal regional cerebral (primary) and renal oxygen saturation and –extraction. 
Furthermore, to find an effect on the redistribution of blood after birth expressed as CROR. 
 
Hypothesis: Sildenafil administration during FGR in pregnancy will through improvement of 
placental function reduce the need for brain sparing, resulting in a lower cerebral oxygen 
saturation, a higher renal oxygen saturation, a higher cerebral FTOE and a lower renal 
FTOE, end finally a lower CROR, compared to the placebo exposed infants.  
 
Methods 
After parental consent renal (and cerebral) oxygen saturation will be measured in infants 
admitted to the NICU according to this time schedule: 
Day 1-5: 203 hours a day, between two standard moments of care, without extra 
disturbances for the infants, then once a week on Days 7, 14, 21, 28, 36 (+/1 2 days), or until 
discharge. 
The sensor will be placed in the left flank (if not possible: right flank). Be means of two-sided 
adhesive tape suitable for the extreme sensitive skin (Mepitel®). The adhesive of the sensor 
will not be used in order to prevent irritation of the skin. The tip of the sensor will be placed 
right next to the spine. The diaper may be wrapped around the sensor. The infant is allowed 
to be positioned in any way suitable.  Standard cerebral measurements will be performed by 
placing the sensor parietotemporally. 
Every participating center can make use of their own available NIRS devices and sensors. 
We will correct for known differences in differences in hind side.  One device is used per 
infant per measurement.  
Every measurement-day during the start of the two-three hour measurement, several 
parameters need to be documented: 
 
- PaCO2, Hb (during measurement, or from maximal 12 hours prior to measurement) 
- blood pressure (systole/diastole/mean arterial pressure) 
- type/doses catecholamines  
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- ventilator mode and pressures  
- position (prone/supine, left/right)  
- timing (start-stop), amount, and type of feeding.  
 
Statistics 
We will test for differences between mean oxygen saturation of the renal region (and cerebral 
region) of all available data per day, after removing artifacts. We will compare between both 
groups: rcSO2, rrSO2, cFTOE, rFTOE, CROR  using a Student-t-test.  
 
Sample size calculation 
In order to detect a relevant difference between cerebral oxygen saturation (SD 7%) of 5% 
between both groups[100], with 90% power, an alpha of 5%, we will need to include 2x42 
infants. 
In order to have enough data every measurement day, at least the First five days after birth, 
we account for a dropout rate of approximately 10%. We will therefore include 92 infants 
from the Strider study.   
Participating centers: UMCG, UMCU, Erasmus MC, Radboud UMC, VUMC, Maxima MC.  
 
 
 
 
14.4 Analysis of the placenta.  
Placental dysfunction is often the underlying mechanism of FGR. Placental pathology has 
been described in relation to both early and late FGR, usually in retrospective cohort studies 
[101]. Sildenafil induces vasodilatation on both sides of the placenta: in the maternal 
placental bed and fetal vasculature (parenchymal/chorionic vessels) with potential positive 
effects on growth [101-103].Effects of these specific vascular changes on placenta bed, 
basal plate and placental parenchyma in relation to changes in methylation patterns 
(maternal fetal as well as placental), immunologic changes and placental pathology need 
further analysis in relation to clinical outcome. Also analysis of maternal and fetal (cord) 
blood regarding markers of these changes need analysis.     
Objectives of this sub study in the strider study:  
1. To analyse the specific effect of Sildenafil on the spiral arteries (placentabed vessels) in 
relation to pathology the placenta.  
2. To analyse the pathogenesis of severe early FGR (placebo and non-randomised group) 
3. To relate the results of both groups to outcome and follow up 
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4. To try to come to (bio)markers of FGR 
 
The investigations oft the placenta will comprise standard macroscopy and microspopy 
(immunohistochemic staining) according to local protocol.  Tissue blocks will be stored 
(standard procedure) and presented to the pathologists of the University Medical Center 
Groningen or Maastricht University Medical Center for central revision of microscopy. 
Additional system biologic investigations such as methylation studies in both maternal 
vascular tissue and parenchymal tissue, immunologic cel subsets (such as M1/M2 
macrophages) and vascular markers will be analysed in these two centers as well. Tissue 
biopsies of placenta bed, basal plate and placental parenchyma will be taken just after 
delivery and processed by fixing in RNA later and frozen in -80 degrees in all centers 
separately and stored until transport to UMCG or MUMC for analysis. Maternal and fetal 
(cord) blood will be processed and used for biomarkers and in applicable centers used for 
flowcytometry (immunologic changes, needs immediate processing)   
 
Participating centres: all participating centres of the STRIDER study.  
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